PINNA, ANNALISA
 Distribuzione geografica
Continente #
EU - Europa 48219
NA - Nord America 1723
AS - Asia 170
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
Totale 50120
Nazione #
IT - Italia 47785
US - Stati Uniti d'America 1714
UA - Ucraina 172
CN - Cina 148
SE - Svezia 94
DE - Germania 54
FI - Finlandia 38
GB - Regno Unito 37
VN - Vietnam 22
BE - Belgio 13
FR - Francia 11
CA - Canada 9
RU - Federazione Russa 4
BR - Brasile 3
EU - Europa 3
NL - Olanda 3
PL - Polonia 3
ES - Italia 2
CH - Svizzera 1
CL - Cile 1
HR - Croazia 1
MU - Mauritius 1
PT - Portogallo 1
Totale 50120
Città #
Cagliari 47695
Fairfield 250
Woodbridge 237
Chandler 222
Ann Arbor 150
Wilmington 112
Seattle 107
Ashburn 99
Houston 96
Cambridge 91
Jacksonville 81
Dearborn 71
Nyköping 71
Nanjing 37
Beijing 32
Boston 26
Dong Ket 22
San Diego 14
Brussels 13
Helsinki 12
Nanchang 10
Shenyang 10
Falls Church 9
Hebei 9
Boardman 8
Toronto 8
Milan 7
Redwood City 7
Jiaxing 6
Mountain View 6
Oristano 6
Padova 6
Jinan 5
Kunming 5
Norwalk 5
Grottammare 4
Rome 4
Tianjin 4
Zhengzhou 4
Chicago 3
Cracow 3
Hangzhou 3
Hefei 3
Los Angeles 3
Orange 3
Sestu 3
Atlanta 2
Auburn Hills 2
Bolzano 2
Chengdu 2
Guangzhou 2
Indiana 2
Nuoro 2
Sassari 2
Shanghai 2
Verona 2
Xian 2
Aci Catena 1
Baotou 1
Bay Springs 1
Borås 1
Changsha 1
Fuzhou 1
Genoa 1
Genova 1
Gunzenhausen 1
Lanzhou 1
London 1
Montreal 1
Ningbo 1
Phoenix 1
Pieve D'alpago 1
Potenza 1
Quzhou 1
Redmond 1
Saint Albans 1
San Mateo 1
Shaoxing 1
Taizhou 1
Uppsala 1
Veroli 1
Villeurbanne 1
Walnut 1
Zagreb 1
Zurich 1
Totale 49632
Nome #
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 3132
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 2764
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2461
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway 2374
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2336
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2252
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2247
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2211
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2112
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease 2057
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 1881
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies 1848
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists 1840
Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age 1811
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 1737
null 1651
Pharmacological therapy of Parkinson's disease: current options and new avenues 1431
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1427
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 1426
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 1425
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1234
Antiparkinsonian actions and interactions of adenosine antagonists 1224
null 1012
null 967
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 912
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 893
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 867
null 801
null 704
null 410
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 405
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 330
Influence of Age and Genetic Background on Ethanol Intake and Behavioral Response Following Ethanol Consumption and During Abstinence in a Model of Alcohol Abuse 57
Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson’s disease 44
Subchronic-intermittent caffeine amplifies the motor effects of amphetamine in rats 14
Totale 50297
Categoria #
all - tutte 52151
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52151


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182932 0000 00 433530 584556406423
2018/20193924 188360982650 305263 209203 101180279204
2019/202012845 57340895140 51533308 1720315 234321188390
2020/202115804 4845866975147 34191543 1062739 290790614433
2021/20223056 317232151142 220225 284189 218351323404
2022/20233140 455676566405 420425 1930 0000
Totale 50297